 monoclon antibody-purg autolog bone marrow transplant therapi multipl myeloma eleven patient plasma cell dyscrasia underw high-dos chemoradiotherapi anti-b-cel monoclon antibodi moab autolog bone marrow transplant abmt major patient durie-salmon stage myeloma diagnosi chemotherapi radiotherapi time abmt patient good perform statu karnofski score marrow tumor cell patient residu monoclon marrow plasma cell patient high-dos melphalan total bodi irradi tbi complet respons partial respons toxic death median rang day PT untransfus platelet median day PT patient natur killer cell cytotoxic/suppressor cell earli PT return cell month PT normal ratio year PT polyclon marrow plasma cell patient transplant complet respond return paraprotein myeloma interferon therapi patient aliv month PT disease-fre month PT preliminari studi confirm high-dos melphalan tbi high respons rate unexpect toxic patient sensit diseas moab-bas purg techniqu engraft follow-up short- long-term outcom post-abmt pretreat patient abmt altern treatment strategi diseas cours